Tonix Pharmaceuticals Inc. (NASDAQ: TNXP) stock fell at last close by 4.46% however the TNXP stock-price gains by 1.9% in the after-hour trading session. Tonix is a clinical-stage pharmaceutical business dedicated on finding, licencing, acquiring, and producing small molecules and biologics to cure, protect, and relieve human illness.
TNXP stock’ Important Upcoming Event
Tonix Pharmaceuticals Holding Corp. announced that an oral presentation at the American College of Rheumatology (ACR) Convergence 2021 has been accepted. The ACR Convergence 2021 will take place virtually between November 5 and 9, 2021.
Recent Development
Tonix Pharmaceuticals has stated that its research cooperation with Columbia University has been broadened. The study will look at immunological responses to COVID-19 in healthy individuals who have cured or were asymptomatic after contracting the virus. In vitro T cell and antibody responses to SARS-CoV-2, the virus that causes COVID-19, are also studied. The study aims to close key gaps in our knowledge of COVID-19’s precise immune responses and lay the groundwork for targeted therapy, which will allow vaccinations and treatments to be tailored to specific individuals.
Seth Lederman, President and CEO of Tonix said that they are eager to expand their research cooperation with Columbia University on these precision medicine technologies, as well as possibly create novel monoclonal antibody therapies, considering the success and outcomes of the initial phase of these initiatives.
Furthermore,
Ilya Trakht, Ph.D., Associate Research Scientist, and Sergei Rudchenko, Ph.D., Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, are the collaboration’s two primary investigators.
Dr. Trakht is investigating T cell and antibody responses in a number of methods, including activating T cells in vitro with CoV-2 antigens and producing completely human monoclonal antibodies against SARS-CoV-2 at the cellular level. Dr. Rudchenko is working on anti-idiotypes based on DNA aptamers for monoclonal antibodies discovered by Dr. Trakht. Such aptamers offer the ability to uncover biomarkers for protective CoV-2 immunity and speed up the development of COVID-19 vaccines based on precision medicine.
